Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 242-243

  Zhang, Weiwei ^a,b   Hu, Renming ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; EXPERIMENTAL MOUSE; HISTOLOGY; HUMAN; HYPOTHESIS; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RISK REDUCTION; VALIDATION PROCESS;

DIABETES MELLITUS; HUMANS; INCIDENCE; MALE; MICROVESSELS; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 72449144062     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.09.042     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts and figures 2008 (2008), American Cancer Society, Atlanta
2. Kristal A.R., Cohen J.H., Qu P., et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11 8 (2002) 719-725
3. IDF-Atlas, 3rd ed., 2006.
4. Fong D.S., Aiello L.P., Ferris III F.L., et al. Diabetic retinopathy. Diab Care 27 10 (2004) 2540-2553
5. LeRoith D., Novosyadlyy R., Gallagher E.J., et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diab 116 Suppl. 1 (2008) S4-S6
6. Waters K.M., Henderson B.E., Stram D.O., et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169 8 (2009) 937-945
7. Calton B.A., Chang S.C., Wright M.E., et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18 5 (2007) 493-503
8. Kasper J.S., and Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 11 (2006) 2056-2062
9. Bonovas S., Filioussi K., and Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47 6 (2004) 1071-1078
10. Hsing A.W., Chua Jr. S., Gao Y.T., et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93 10 (2001) 783-789
11. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92 23 (2000) 1910-1917
12. Giovannucci E., and Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132 6 (2007) 2208-2225
13. Evans J.M., Donnelly L.A., Emslie-Smith A.M., et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 7503 (2005) 1304-1305
14. Frayling T.M., Colhoun H., and Florez J.C. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51 10 (2008) 1757-1760
15. Malavige L.S., and Levy J.C. Erectile dysfunction in diabetes mellitus. J Sex Med 6 5 (2009) 1232-1247
16. Cameron N.E., and Cotter M.A. Erectile dysfunction and diabetes mellitus: mechanistic considerations from studies in experimental models. Curr Diab Rev 3 3 (2007) 149-158
17. Brooks J.D. Anatomy of the lower urinary tract and male genitalia. In: Wein A.J. (Ed). Campbell-Walsh urology. 9th ed. (2007), Sauders Elsevier, Philadelphia, PA
18. Thompson I.M., Tangen C.M., Goodman P.J., et al. Chemoprevention of prostate cancer. J Urol 182 2 (2009) 499-507
19. Pareek G., Shevchuk M., Armenakas N.A., et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169 1 (2003) 20-23
20. Sogno I., Venè R., Sapienza C., et al. Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res 181 (2009) 71-76
21. Figg W.D., Arlen P., Gulley J., et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28 4 Suppl. 15 (2001) 62-66
22. Ng Q.S., Goh V., Milner J., et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8 2 (2007) 111-118
23. Ahmad I., Sansom O.J., and Leung H.Y. Advances in mouse models of prostate cancer. Expert Rev Mol Med 10 (2008) e16
24. Tesch G.H., and Nikolic-Paterson D.J. Recent insights into experimental mouse models of diabetic nephropathy. Nephron Exp Nephrol 104 2 (2006) e57-e62
25. Tosetti F., Ferrari N., De Flora S., et al. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16 1 (2002) 2-14